The Rotavirus Vaccine is a critical tool in the prevention of rotavirus infections, which are a leading cause of severe diarrhea and dehydration in infants and young children worldwide. Rotavirus is highly contagious and spreads through the fecal-oral route, making it particularly challenging to control. The vaccine helps to protect against rotavirus by stimulating the immune system to produce antibodies that target the virus. There are two main types of rotavirus vaccines available: the oral live attenuated vaccine and the oral inactivated vaccine. Both types of vaccines are administered orally and have been shown to be safe and effective in preventing rotavirus infections.
The live attenuated rotavirus vaccine is administered in two or three doses, depending on the vaccine formulation, typically starting at around 6 to 8 weeks of age. This vaccine contains weakened forms of the rotavirus strains that are most commonly associated with severe illness. When administered, the vaccine stimulates the immune system to produce a protective response against these strains, reducing the risk of rotavirus infection and its complications. The inactivated rotavirus vaccine is administered in two doses, typically starting at around 2 to 6 months of age. This vaccine contains killed rotavirus strains and is administered orally in a liquid form. Similar to the live attenuated vaccine, the inactivated vaccine stimulates the immune system to produce antibodies against rotavirus, providing protection against infection.
Both types of rotavirus vaccines have been shown to be highly effective in preventing severe rotavirus gastroenteritis and reducing hospitalizations and deaths associated with rotavirus infection. Vaccination with the rotavirus vaccine has led to significant declines in the incidence of rotavirus-related hospitalizations and deaths in countries where it has been introduced into routine immunization programs. The rotavirus vaccine is typically recommended as part of routine childhood immunization schedules in many countries around the world. It is considered safe and well-tolerated, with the most common side effects being mild and temporary, such as fever or mild diarrhea.
Submit your abstract Today
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Prophylactic and Molecular Approaches for Mitigating Human Influenza A Viruses: i. Evaluating influenza Vaccine Effectiveness in the Older population ii. Down-regulation of influenza virus genes with novel siRNA-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a Novel Multi-component Vaccine to Address the Burden of Otitis Media in High-Risk Populations
Ayesha Zahid, Griffith University, Australia
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Immunosuppression in COVID-19 Patients and Emerging Fungal Infections: Vaccines, Diagnosis and Strategies to Treat Comorbidities
K R Aneja, Kurukshetra University, India
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Why is the vaccine life-threatening if people get a fever after a COVID-19 vaccination
Yacob Mathai, Marma Health Centre, India
Title : Barriers to polio eradication in South Asia: A systematic review
Awranoos Ahadi, Bolan Medical College, Pakistan